VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN (Pelareorep) in Combination With Lenalidomide or Pomalidomide

Trial Profile

VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN (Pelareorep) in Combination With Lenalidomide or Pomalidomide

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Pelareorep (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms MUK eleven; VIRel
  • Most Recent Events

    • 14 Sep 2017 According to an Oncolytics Biotech media release, this trial, runs through the Myeloma UK Clinical Trial Network (CTN) in collaboration with charity Myeloma UK, the University of Leeds and and Celgene.
    • 14 Sep 2017 According to an Oncolytics Biotech media release, preliminary data are expected to be available in the first quarter of 2018.
    • 14 Sep 2017 According to an Oncolytics Biotech media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top